Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC

NCT03450967 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Durvalumab Plus Tremelimumab

Sponsor

Samsung Medical Center